Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367951 | 0.87 | RAB9A (0.56) | RAB9ANPC1CYP2C9NR4A2POLB | |
| SCHEMBL2489707 | 0.85 | RAB9A (0.53) | RAB9ANPC1CYP2C9NR4A2POLB | |
| SCHEMBL3367638 | 0.85 | RAB9A (0.53) | RAB9ANPC1CYP2C9NR4A2POLB | |
| SCHEMBL3367652 | 0.82 | RAB9A (0.51) | RAB9ANPC1CYP2C9NR4A2POLB | |
| SCHEMBL2486359 | 0.81 | NPC1 (0.49) | RAB9ANPC1CYP2C9NR4A2POLB | |
| SCHEMBL3340526 | 0.81 | PTGS1 (0.41) | RAB9ANPC1POLBSMN1; SMN2TSHR | |
| SCHEMBL3367434 | 0.80 | RAB9A (0.65) | RAB9ANPC1CYP2C9NR4A2POLB | |
| SCHEMBL3773111 | 0.79 | CYP2C9 (0.61) | RAB9ANPC1CYP2C9NR4A2 | |
| SCHEMBL14793627 | 0.78 | RAB9A (0.54) | RAB9ANPC1CYP2C9NR4A2POLB | |
| SCHEMBL3368461 | 0.76 | NPC1 (0.70) | RAB9ANPC1CYP2C9NR4A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404848-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-03-26 | — | — | US | claimed |
| EP-2041133-B1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-13 | — | — | EP | claimed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | claimed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | claimed |
| US-8404848-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| EP-2041133-B1 | DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | NR4A2, NR4A3, NCOR1 | RAB9A 3591/4885NPC1 1018/4885CYP2C9 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.